image description

Andrew J. Finn

Partner

Andrew J. Finn

Partner
New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588
[email protected]
Andrew Finn is a partner in the Firm’s Litigation Group. Mr. Finn has advised leading U.S. and multinational companies, as well as individual executives and business owners, on some their most complex commercial disputes.

Mr. Finn’s experience has run the gamut from securities class actions to contractual disputes and competition cases for clients in a wide-range of industries, including finance and banking, transportation, energy, entertainment and health care. He has litigated cases in state and federal trial and appellate courts, and has extensive arbitration experience. He also has advised on corporate monitorship and other large-scale government settlement compliance matters. 

Mr. Finn also devotes time to pro bono matters. As an assistant federal defender secondee in the Southern District of New York, Mr. Finn successfully defended criminal defendants in negotiations with the U.S. Attorneys’ Office and at trial. Mr. Finn also has successfully represented, and continues to represent, indigent clients seeking asylum in the United States.

SELECTED REPRESENTATIONS

  • Volkswagen AG and AUDI AG, in multi-district litigation centered in the Northern District of California arising out of the companies’ diesel vehicle emissions issues.
  • A leading Broadway producer and theater operator, in a bench trial of breach of contract and fiduciary duty claims brought by the co-owner of a San Francisco theater business in the Delaware Court of Chancery.  The trial court dismissed the principal claims and awarded no damages.  
  • A former director of a Hollywood film company, in a $110 million lawsuit in New York state court brought by one of the company’s creditors alleging fraud in connection with a lending facility. The New York Appellate Division, First Department, affirmed on appeal the trial court’s dismissal of all claims, with prejudice.
  • Standard Chartered Bank, in multi-district litigation, arbitrations and ongoing bankruptcy proceedings in the Southern District of New York arising from Bernard Madoff’s failed brokerage firm. In 2017, Standard Chartered obtained dismissal of a bankruptcy claim seeking more than $300 million. Standard Chartered previously obtained dismissal of two putative class actions.
  • Bank J. Safra Sarasin AG, in bankruptcy proceedings in the Southern District of New York arising from Bernard Madoff’s failed brokerage firm.
  • Numerous securities underwriters, in class action and opt-out securities litigation arising from initial public offerings and secondary offerings of securities.
  • JPMorgan Chase and other leading U.S. securities issuers and institutional investors, in responding to and litigating alleged violations of the short-swing profit rule under Section 16b of the Securities Exchange Act.
  • Microsoft, in a jury trial of antitrust claims brought by software company Novell, Inc. in the District of Utah.  Novell had sought about $4 billion in damages from Microsoft for purported anticompetitive conduct in the market for PC operating systems. Ultimately, the district court granted Microsoft’s post-trial motion for judgment as a matter of law, dismissing Novell’s case in its entirety, with the U.S. Court of Appeals for the Tenth Circuit affirming the lower court’s decision.
  • Barclays Bank, in private antitrust class actions seeking billions of dollars in damages and investigation by a multistate group of attorneys general arising from alleged manipulation of Euribor and LIBOR.
  • Saltchuk Resources, Inc., in class and individual antitrust actions brought by direct and indirect purchasers in the District of Puerto Rico and Middle District of Florida arising from alleged price-fixing in the ocean freight shipping.
  • A major U.S. energy company, in a putative class action challenging a state tax exemption for a multi-billion dollar natural gas project. The trial court dismissed all claims with prejudice. 
  • A major Japanese pharmaceutical company, in an ICC arbitration arising from its acquisition of a Mexican pharmaceutical business.